Find a Tender
complete
Official procurement procedure
Manufacture and testing of overencapsulated tablets and placebo capsules for research purposes - LAMDARCT clinical trial
No classification published
Location not published
Published value
Not published
Submission deadline Not published
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: Belfast Health and Social Care Trust: "Manufacture and testing of overencapsulated tablets and placebo capsules for research purposes - LAMDARCT clinical trial". Published status: complete. Published value: Value not published. 1 published lot. Submission deadline not published. See the official notice for participation instructions.
| Contracting Authority | Belfast Health and Social Care Trust | Scope & Categories | Not published | Submission Window | complete No deadline published |
|---|---|---|---|---|---|
| Submission Gateway | Direct notice route | Legal Basis & Regime | Standard procurement | Estimated Value (exc. VAT) | Not published |
Bidder Intelligence · Authority Profile: Belfast Health and Social Care Trust
Market Analytics
Derived from OCDS awards & bid statistics
Published history for Belfast Health and Social Care Trust. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Published-to-award variance
Not availableInsufficient comparable data
Competition Density
10Bids / Report
Supplier ConcentrationHigh Concentration
MET HEALTHCARE LIMITEDTop vendor: 84.5% of attributable valuePayment Terms
Check noticePublished terms
Coverage: 81 active published awards; 25 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Published-to-award variance compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Historical Awarded Suppliers With This Authority:
| Supplier Name | Historic Awards | Attributable GBP Value |
|---|---|---|
| MET HEALTHCARE LIMITED | 1 win | £935,340 |
| RESUSCITATION COUNCIL (UK) | 1 win | £171,640 |
Procedure terms
Contracting AuthorityBelfast Health and Social Care Trust | Procedure methodNot published | Procurement categoryNot published |
Statuscomplete | Framework / DPSNot published | CompetitionNot published |
Above thresholdNot published | Legal basisNot published | Tender period startsNot published |
Clarification deadlineNot published | Electronic submissionNot published | Submission languagesNot published |
Published21 Jan 2026, 09:15 GMT | Last source update21 Jan 2026, 09:15 GMT | Recurring procurementNot published |
ClassificationNot published | ||
Delivery areaLocation not published | ||
OCIDocds-h6vhtk-05f108 | ||
What is being bought
This procurement is for the manufacture and testing of over encapsulated tablets and placebo capsules for research purposes - LAMDARCT clinical trial
What changed
From the official release history
- Official notice release published
21 Jan 2026, 09:15 GMT - Official notice release published
8 Dec 2025, 15:58 GMT - Status changed to complete
8 Dec 2025, 15:49 GMT - Official notice release published
8 Dec 2025, 15:49 GMT - Buyer information updated
8 Dec 2025, 15:49 GMT
Lots and requirements (1)
Published by the contracting authority
- Lot 1 · #1Individual lot title not publishedcompletePublished valueNot publishedThe source published no individual title or description for this lot.Contract periodNot publishedEligibilityNot publishedOptions / renewalNot published
Timeline
- Procedure published
21 Jan 2026, 09:15 GMT - Award active
Not published · Not published - Contract active
Signed 19 Jan 2026, 00:00 GMT · £494,448
Commercial outcome and competition
Awards ALMAC CLINICAL SERVICES LIMITED Not published · Not published · active |
Contracts Manufacture and testing of overencapsulated tablets and placebo capsules for research purposes - LAMDARCT clinical trial £494,448 · signed 19 Jan 2026, 00:00 GMT · active Contract period: 19 Jan 2026, 00:00 GMT — 5 Jan 2030, 23:59 GMT |
Bid statisticsNo aggregate bid statistics published |
Buyer and organisations in this procedure
Belfast Health and Social Care Trust
Contracting authority GB-PPON-PLQJ-5727-JCLRDocuments (1)
Official links; attachments are not copied
Related procedures (0)
No related procedures published
Planning and rationale
Planning budgetNot published |
No-engagement rationaleNot published |
Procedure rationaleSchedule 5, (2) The public contract concerns the production of a prototype, or supply of other novel goods or services, for the purpose of (c) other research, experiment, study or development.
Age-related macular degeneration (AMD) is a leading cause of visual loss. There are two main forms of AMD: dry and wet. The current wet AMD treatment is intravitreal antiVEGF injections, repeated every 4-12 weeks. Due to the cost of the medication, the route and frequency of administration, this treatment is a significant burden on the NHS budget. An additional treatment option for wet AMD is L-dopa. L-dopa is a widely available drug (used in treatment of Parkinson's), typically in the form of Carbidopa-L-Dopa. It is taken as an oral tablet and is significantly cheaper than the antiVEGF injections.
The study will be a placebo-controlled clinical trial. Eligible patients will be randomised to receive either 100mg L-DOPA+25mg carbidopa or placebo twice a day, for 24 months, in addition to the current standard of care to determine if this is a more cost-effective and easier-to-administer treatment regime than the current standard of care.
To 'blind' this clinical trial (to reduce bias) requires the development, manufacture and testing of over encapsulated 100mg L-DOPA+25mg carbidopa tablets and development and manufacture of matching placebo capsules. The expertise required to develop and manufacture these capsules in the quantity required for this trial requires outsourcing to a manufacturer licensed by the MHRA possessing the necessary technical expertise. |